Relationship between symptom severity and steroid variation in women with premenstrual syndrome: study on serum pregnenolone, pregnenolone sulfate, 5 alpha-pregnane-3,20-dione and 3 alpha-hydroxy-5 alpha-pregnan-20-one.
Relationship between symptom severity and steroid variation in women with premenstrual syndrome: study on serum pregnenolone, pregnenolone sulfate, 5 alpha-pregnane-3,20-dione and 3 alpha-hydroxy-5 alpha-pregnan-20-one.
复制标题
DOI：
10.1210/jcem.81.3.8772579
复制
发表时间：
1996-03
期刊：
影响因子：
--
通讯作者：
Michelle D. Wang;L. Seippel;R. Purdy;Tobias B ckstr m
中科院分区：
文献类型：
--
作者：
Michelle D. Wang;L. Seippel;R. Purdy;Tobias B ckstr m
经前综合症（PMS）症状与孕烯醇酮（Pe）、硫酸孕烯醇酮（PS）、5α-孕烷-3,20-二酮（5α-DHP）、3α-羟基-5α-孕烷-20-酮（5α-THP）、LH、17β-雌二醇（E2）和黄体酮的血清水平之间的关系 (P) 使用每日测量结果对 12 名患者的 2 个连续月经周期进行了调查。还在 8 名对照女性的 1 个周期内测量了相应的激素。 Pe、PS、5α-DHP 和 5α-THP 在月经周期内表现出显着的周期性，并且在 PMS 患者和对照中与 P 变化具有很高的相关性。 PMS 患者与对照组之间黄体期 Pe、PS、5α-DHP、5α-THP 和 LH 的平均血清浓度没有显着差异，而 PMS 患者中 E2 水平显着升高，P 水平显着降低。将症状评分的变化与每位女性体内激素水平的变化进行比较。症状峰值在血清 P、Pe、5α-DHP 和 5α-THP 峰值后延迟 3-4 天。然而，PMS患者的血浆PS峰值出现在症状峰值的同一天或仅前1天。比较所研究的 2 个周期时，黄体期 E2、Pe 和 PS 浓度较高的周期中出现更多阴性症状，而黄体期 5 α-DHP 和 5 α-THP 浓度较高则与 PMS 患者症状评级改善相关。这些结果表明，上述类固醇与经前综合症患者痛苦症状的严重程度有关。
The relationship between symptoms of premenstrual syndrome (PMS) and serum levels of pregnenolone (Pe), pregnenolone sulfate (PS), 5 alpha-pregnane-3,20-dione (5 alpha-DHP), 3 alpha-hydroxy-5 alpha- pregnan-20-one (5 alpha-THP), LH, 17 beta-estradiol (E2), and progesterone (P) was investigated during 2 consecutive menstrual cycles in 12 patients using daily measurements. Corresponding hormones were also measured during 1 cycle in 8 control women. Pe, PS, 5 alpha-DHP, and 5 alpha-THP showed a significant cyclicity within menstrual cycles and a high rate of correlation with P variation in both PMS patients and controls. No significant difference was found between PMS patients and controls in average serum concentrations of Pe, PS, 5 alpha-DHP, 5 alpha-THP, and LH during the luteal phase, whereas a significantly higher level of E2 and a lower level of P were observed in PMS patients. The variation in symptom scores was compared with that in hormone levels within each woman. The symptom peak showed a delay of 3-4 days after the serum P, Pe, 5 alpha-DHP, and 5 alpha-THP peaks. However, the plasma PS peak appeared on the same day or only 1 day before the symptom peak in PMS patients. When comparing the 2 cycles studied, more negative symptoms occurred in cycles with higher luteal phase E2, Pe, and PS concentrations, whereas higher luteal phase 5 alpha-DHP and 5 alpha-THP concentrations were associated with improved symptom ratings in PMS patients. These results suggest that the mentioned steroids are related to the severity of distressing symptoms in PMS patients.